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Abstract
Background: We assessed breast cancer mortality in older versus younger women according to race/ethnicity,
neighborhood socioeconomic status (nSES), and health insurance status.
Methods: The study included female breast cancer cases 18 years of age and older, diagnosed between 2005 and
2015 in the California Cancer Registry. Multivariable Cox proportional hazards modeling was used to generate
hazard ratios (HR) of breast cancer specific deaths and 95% confidence intervals (CI) for older (60+ years) versus
younger (< 60 years) patients separately by race/ethnicity, nSES, and health insurance status.
Results: Risk of dying from breast cancer was higher in older than younger patients after multivariable adjustment,
which varied in magnitude by race/ethnicity (P-interaction< 0.0001). Comparing older to younger patients, higher
mortality differences were shown for non-Hispanic White (HR = 1.43; 95% CI, 1.36–1.51) and Hispanic women (HR =
1.37; 95% CI, 1.26–1.50) and lower differences for non-Hispanic Blacks (HR = 1.17; 95% CI, 1.04–1.31) and Asians/
Pacific Islanders (HR = 1.15; 95% CI, 1.02–1.31). HRs comparing older to younger patients varied by insurance status
(P-interaction< 0.0001), with largest mortality differences observed for privately insured women (HR = 1.51; 95% CI,
1.43–1.59) and lowest in Medicaid/military/other public insurance (HR = 1.18; 95% CI, 1.10–1.26). No age differences
were shown for uninsured women. HRs comparing older to younger patients were similar across nSES strata.
Conclusion: Our results provide evidence for the continued disparity in Black-White breast cancer mortality, which
is magnified in younger women. Moreover, insurance status continues to play a role in breast cancer mortality, with
uninsured women having the highest risk for breast cancer death, regardless of age.
Keywords: Mortality, Younger and older age, Breast cancer
Background
According to American Cancer Society, the 10-year prob-
ability of developing breast cancer increases with age,
from 0.5% in women 30 years of age to 3.9% in those age
70 and the median age of diagnosis is 62 [1]. In 2015,
58.0% of all incident breast cancers in the United States
(U.S.) occurred in women over the age of 60 [2]. With a
rising number of older women in the U.S., understanding
the breast cancer burden, including survival outcomes in
these women is important. While different age cut-offs are
used to define younger versus older patients, it is well
recognized that women less than 40 years of age are more
likely to develop breast cancer with more aggressive sub-
type and worse clinicopathological features [1, 3]. Findings
from published studies report differences in breast cancer
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mortality and survival by age, showing that women diag-
nosed with breast cancer at less than 40 years of age have
a lower survival than older patients [4–6]. Studies focused
on breast cancer mortality have also reported that younger
compared to older breast cancer patients have higher
breast cancer mortality, regardless of age-cut off [7, 8].
While a wealth of published data exists on factors that im-
pact breast cancer mortality, including race/ethnicity, so-
cioeconomic status, and other sociodemographic factors
[9–11], limited research exists on whether associations
vary by age at diagnosis.
Few studies have been published on factors associated
with breast cancer mortality in older women when com-
pared to younger patients, with varying age cut-offs [12–
17]. Published results show that older women with
worse breast cancer health outcomes are more likely to
be racial/ethnic minority women, have a lower sociode-
mographic status, and have no health insurance [13, 15,
17]. Under-treatment and/or more comorbidities in
older women compared to younger women could be rea-
sons for the observed higher breast cancer mortality in
these women [12, 13, 16]. It has been reported that as
women age, they are less likely to pursue or be offered
aggressive treatment [12]. To our knowledge, studies of
age differences in survival have not considered potential
heterogeneity by sociodemographic factors, which would
aid in better understanding breast cancer outcomes.
Using data from the population-based California Cancer
Registry (CCR), our study assessed breast cancer mortality
differences between younger (age 18–59) and older (age
60 and above) breast cancer patients according to race/
ethnicity, health insurance, and socioeconomic status,
while controlling for patient and clinical variables.
Methods
Study population
We obtained information from the CCR for female Cali-
fornia residents ages 18 years and older at diagnosis,
who were diagnosed with a first, primary invasive breast
cancer [International Classification of Disease for Oncol-
ogy, 3rd Edition, (ICD-O-3) site codes C50.0–50.9]
during January 1, 2005 through December 31, 2015 (n =
219,266). Patients were excluded from the analysis hier-
archically as follows: diagnosis by death certificate or
autopsy only (n = 889) or diagnosis not microscopically
confirmed (n = 1698); ICD-O-3 histologic type other
than: 8000, 8001, 8010, 8020, 8022, 8050, 8140, 8201,
8211, 8230, 8255, 8260, 8401, 8453, 8480, 8481, 8500–
8525, or 8575 (n = 3654); tumor size missing because
unknown (n = 8347), no tumor noted (n = 510), micro-
scopic (n = 2250), diffuse (n = 608), or mammographic
diagnosis only (n = 59); age < 60 insured by Medicare
(n = 513); no follow-up (n = 269); residential address that
was uncertain or not geocodable (n = 6292). The study
included 192,932 patients, of whom 94,076 were younger
(age 18–59) and 98,856 were older (age 60 and above,
up to age 109) patients.
Data acquisition
Data from the CCR, mostly derived from the patient’s
medical record, were used to obtain age at diagnosis,
marital status, residential address at diagnosis, stage at
diagnosis, tumor size (in centimeters), lymph node in-
volvement, histology, grade (I, II, III/IV, or unknown),
and hormone receptor [estrogen receptor (ER), proges-
terone receptor (PR), and human epidermal growth fac-
tor receptor 2 (HER2)] status. The CCR followed
patients for vital status, from linkage with vital records,
to December 31, 2015 for this study.
For the variables of interest in the present report, we
used data from the medical record to classify race/ethni-
city as non-Hispanic White (NHW), non-Hispanic Black,
Hispanic, Asian/Pacific Islander (API), or other/unknown;
and primary and secondary source of payment were used
to classify insurance status, as private only, Medicare only/
Medicare + private, any Medicaid/military/other public,
no insurance, and unknown; in the CCR, payer status is
coded based on the most extensive insurance type across
the diagnosis to treatment continuum. We used a multi-
component measure of neighborhood socioeconomic
(nSES), based on patients’ residential census block group
at diagnosis. This measure incorporated the 2000U.S.
Census (for cases diagnosed in 2005) and the 2006–2010
American Community Survey data (for cases diagnosed in
2006 and forward) on education, occupation, unemploy-
ment, household income, poverty, rent, and house values
[18, 19]. Each patient was assigned a nSES quintile, based
on the distribution of socioeconomic status across census
block groups in California.
Statistical analysis
Given the lack of standard for categorizing younger and
older breast cancer patients, we used the median age of the
study population as a cut-off (60 years); younger women in-
cluded those age 18–59 and older included 60+ years. Dif-
ferences in mortality for older and younger women were
examined by two methods. First, comparisons were made
between older and younger patients stratified by race/ethni-
city, insurance status, and nSES, with younger women as
the reference group. Next, models were stratified by age
and comparisons were made between race/ethnicity (non-
Hispanic White as the reference group), insurance status
(private insurance as the reference group), and nSES quin-
tiles (5th quintile as the reference group).
Descriptive statistics were calculated and reported as
percentages for categorical data and means with standard
deviation for continuous variables. Covariates were shown
overall and for younger and older women. Covariates
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examined included: age (continuous and categorical), race/
ethnicity, marital status, insurance status, nSES, whether the
patient was seen at one or more of the National Cancer
Institute-designated Cancer Centers in California (NCICC)
for her breast cancer, American Joint Committee on Cancer
(AJCC) stage at diagnosis, tumor subtype, lymph node in-
volvement, tumor size, tumor grade, and tumor histology.
Follow-up time was calculated as the number of days
between the date of diagnosis and date of death from
breast cancer (ICD 9/10 = 174/C50), the date of death
from another cause, the date of last follow-up (i.e., last
known contact), or the study end date (12/31/2015).
There were 599 deceased patients with an unknown cause
of death which were excluded from all models. Cox pro-
portional hazards regression was used to estimate breast
cancer specific hazard rate ratios (HR) and corresponding
95% confidence intervals (CI). Adjusted models were
stratified by AJCC stage and adjusted for age at diagnosis
(continuous), year of diagnosis (continuous), race/ethni-
city, marital status, insurance status, nSES, whether the
patient was seen at one or more of the NCICC in Califor-
nia for her breast cancer, tumor subtype, lymph node in-
volvement, tumor size, tumor grade, and tumor histology.
Fully adjusted models were additionally adjusted for clus-
tering by block group, using a sandwich estimator of the
covariance structure that accounts for intracluster de-
pendence. The proportional hazards assumption was
tested by examining the correlation between time and
scaled Schoenfeld residuals for all covariates. The propor-
tional hazards assumption was violated for AJCC stage at
diagnosis, tumor subtype, and tumor grade. Stage was in-
cluded as an underlying stratifying variable in the fully ad-
justed Cox regression models reported here, which
allowed the baseline hazards to vary by stage. Additionally,
stratifying the Cox model by tumor subtype and tumor
grade did not meaningfully change the HR for the main
effect of age, so these factors were simply adjusted for in
fully adjusted models. Wald Type 3 tests for interaction
between age group (18–59, 60+) and race/ethnicity, in-
surance status, and nSES and were computed using cross-
product terms, in models adjusted for all statistically
significant (p < 0.05) interactions with age group (race/eth-
nicity, marital status, insurance status, NCICC, tumor sub-
type, and lymph node involvement). Wald tests for trend
across nSES quintiles were computed using quintile num-
ber as an ordinal variable. All statistical tests were carried
out using SAS software version 9.3 (SAS Institute).
Results
Of the total population (n = 192,932), 94,076 (48.7%) were
diagnosed under the age 60 and 98,856 (51.2%) were aged
60 and older. As noted in Table 1, approximately 60% of
the population was NHW, 40% was married, 26% was from
the highest socioeconomic neighborhood, and 58% had
private insurance. Examining clinical factors, 48% of total
patients were diagnosed with stage I breast cancer, 65% had
hormone receptor-positive (ER positive or PR positive)/
HER2-negative tumor subtype, 66% were negative for
lymph node involvement, 35% had a tumor size of 1–2 cm,
42% had a tumor grade of II, 79% had a ductal histology,
and 12% received care at a NCI-designated Cancer Center.
Table 2 shows the multivariable-adjusted breast cancer
specific mortality for older versus younger women ac-
cording to race/ethnicity, health insurance, and nSES.
Overall, older breast cancer patients had a higher risk of
dying from breast cancer than younger patients (HR =
1.35; 95% CI, 1.29–1.40). HRs (95% CIs) comparing
older to younger women were: 1.43 (1.36–1.51) for
NHWs; 1.37 (1.26–1.50) for Hispanics; 1.17 (1.04–1.31)
for non-Hispanic Blacks; and 1.15 (1.02–1.31) for APIs.
A higher risk of dying was shown for older vs. younger
patients for women with private insurance (HR = 1.51;
95% CI, 1.43–1.59) and for those with any Medicaid/
military/other public insurance (HR = 1.18; 95% CI,
1.10–1.26). No significant differences by age were shown
for uninsured patients. HRs by age across nSES quintiles
ranged from 1.30 (95% CI, 1.19–1.41) in the third quin-
tile to 1.42 (95% CI, 1.29–1.56) in fifth quintile.
Table 3 shows HRs stratified for older and younger
women separately, according to race/ethnicity, insurance
status, and nSES. Compared to NHWs, non-Hispanic
Blacks had a higher risk of dying regardless of age group,
with higher HRs for younger (HR = 1.36; 95% CI, 1.25–
1.48) than older (HR = 1.11; 95% CI, 1.01–1.22) patients.
API women had lower risk of dying compared to NHWs in
both age groups: HR (95% CI) was 0.88 (0.82–0.95) in
younger and 0.77 (0.70–0.84) in older patients. No mortal-
ity difference was observed for Hispanics compared to
NHWs in either age group. In younger women, compared
to patients with private health insurance, a higher risk of
breast cancer mortality was observed in women with any
Medicaid/military/other public insurance (HR = 1.49; 95%
CI, 1.41–1.58) and in those with no insurance (HR = 1.96;
95% CI, 1.65–2.32). As noted in the Methods, younger pa-
tients with Medicare insurance were excluded from the
analysis. A higher risk of mortality was shown among older
women with any Medicaid/military/other public insurance
(HR = 1.13; 95% CI, 1.06–1.21) and those with no insurance
(HR=1.57; 95% CI, 1.22–2.03), as compared to privately-
insured patients. No difference was observed for Medicare
only or Medicare plus private insurance in the older group. In
both younger and older women, breast cancer mortality risk
decreased with increasing nSES quintile (P-trend=< 0.0001
for younger and < 0.0001 for older patients).
Recognizing that very young breast cancer patients (< 40
years of age) are more likely to have aggressive tumor sub-
types or to have germline mutations [20], resulting in
higher mortality compared to older patients, we conducted
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Table 1 Patient demographic and clinical characteristics for younger (18–59 years) and older (60+ years) age at breast cancer
diagnosis, California, 2005–2015
All Younger (18–59) Older (60+)
Total Number of Patients 192,932 100.0 94,076 100.0 98,856 100.0
Age (yrs) Mean (SD) 60.2(13.7) 48.8(7.3) 71.2(8.3)
Age category
18–39 10,785 5.6 10,785 11.5 – –
40–49 35,297 18.3 35,297 37.5 – –
50–59 47,994 24.9 47,994 51.0 – –
60–69 49,225 25.5 – – 49,225 49.8
70–79 31,540 16.3 – – 31,540 31.9
80+ 18,091 9.4 – – 18,091 18.3
Race/ethnicity
Non-Hispanic White 116,534 60.4 49,107 52.2 67,427 68.2
Non-Hispanic Black 12,014 6.2 6348 6.7 5666 5.7
Hispanic 36,363 18.8 22,305 23.7 14,058 14.2
Asian/Pacific Islander 25,871 13.4 15,242 16.2 10,629 10.8
Other/unknown 2150 1.1 1074 1.1 1076 1.1
Marital status
Married 77,754 40.3 31,324 33.3 46,430 47.0
Unmarried 107,808 55.9 59,344 63.1 48,464 49.0
Unknown 7370 3.8 3408 3.6 3962 4.0
Neighborhood (block group)
statewide SES quintile
1st (lowest) 23,702 12.3 12,174 12.9 11,528 11.7
2nd 33,174 17.2 15,787 16.8 17,387 17.6
3rd 39,136 20.3 18,584 19.8 20,552 20.8
4th 45,882 23.8 22,231 23.6 23,651 23.9
5th (highest) 51,038 26.5 25,300 26.9 25,738 26.0
Insurance status
Private only 112,154 58.1 71,611 76.1 40,543 41.0
Medicare only or Medicare+Private 40,789 21.1 -a -a 40,789 41.3
Any Medicaid/Military/Other public 33,225 17.2 18,671 19.8 14,554 14.7
No insurance 1598 0.8 1085 1.2 513 0.5
Unknown 5166 2.7 2709 2.9 2457 2.5
National Cancer Institute-–designated
cancer center
No 170,509 88.4 80,161 85.2 90,348 91.4
Yes 22,423 11.6 13,915 14.8 8508 8.6
AJCC Stage
I 91,898 47.6 39,390 41.9 52,508 53.1
II 68,825 35.7 36,785 39.1 32,040 32.4
III 22,492 11.7 13,251 14.1 9241 9.3
IV 7249 3.8 3609 3.8 3640 3.7
2468 1.3 1041 1.1 1427 1.4
Tumor subtype
ER+, PR+/HER2- 125,240 64.9 56,822 60.4 68,418 69.2
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analyses excluding women less than 40 years of age. The
fully adjusted HR (95% CI) comparing women 60 years of
age and older to those less than 60 years was 1.35 (1.30–
1.41), indicating no difference in the magnitude of the asso-
ciation compared to our main analysis including younger
women. Results of analyses for race/ethnicity, health insur-
ance, and nSES stratified by age were not materially differ-
ent after excluding women less than 40 years of age than
those including these younger patients (data not shown).
Discussion
To our knowledge, there are no published reports on
differences in breast cancer mortality between older
compared to younger women according to sociodemo-
graphic characteristics, such as race/ethnicity, insurance
status, and nSES. As such, this study contributes to the
limited literature, showing that breast cancer patients 60
years of age and older had higher breast cancer mortality
risk compared to those less than 60 years, with largest
differences seen among NHW and Hispanic women, and
among women with private insurance.
Our analyses assessed age-related differences in breast
cancer mortality using two approaches. The first in-
volved examining mortality differences in older versus
younger patients within racial/ethnic, insurance, and
nSES groups. In the second approach, we assessed differ-
ences across race/ethnicity, insurance status, and nSES
among younger and older patients. Results of the first
approach showed differential age effects by race/ethni-
city and insurance status, but not by nSES. Although
older women were at higher risk of dying from breast
cancer compared to younger women across all racial/
ethnic groups, differences were smaller for non-Hispanic
Black and API patients than for NHWs and Hispanics.
For insurance status, age-related mortality differences
were more pronounced among privately-insured patients
and no differences were shown for uninsured women.
Finally, in regard to nSES, mortality differences between
older and younger women were not highly variable.
In the second approach, comparisons across race/eth-
nicity, insurance status, and nSES within younger and
older age groups showed mortality risk patterns that dif-
fered between the two age groups. Compared to NHWs,
Table 1 Patient demographic and clinical characteristics for younger (18–59 years) and older (60+ years) age at breast cancer
diagnosis, California, 2005–2015 (Continued)
All Younger (18–59) Older (60+)
ER+, PR+//HER2+ 19,630 10.2 11,808 12.6 7822 7.9
ER-, PR−//HER2+ 9023 4.7 5467 5.8 3556 3.6
Triple negative 19,836 10.3 11,280 12.0 8556 8.7
Unclassified 19,203 10.0 8699 9.2 10,504 10.6
Lymph node involvement
Negative 126,915 65.8 56,446 60.0 70,469 71.3
Positive 64,045 33.2 36,933 39.3 27,112 27.4
Unknown 1972 1.0 697 0.7 1275 1.3
Tumor size (cm)
0.10≤ tumor ≤0.50 13,488 7.0 6275 6.7 7213 7.3
0.50 < tumor ≤1.00 31,342 16.2 12,706 13.5 18,636 18.9
1.00 < tumor ≤2.00 67,792 35.1 31,674 33.7 36,118 36.5
2.00 < tumor ≤5.00 64,694 33.5 34,472 36.6 30,222 30.6
> 5.00 15,616 8.1 8949 9.5 6667 6.7
Grade
Grade I 43,518 22.6 17,726 18.8 25,792 26.1
Grade II 80,909 41.9 37,234 39.6 43,675 44.2
Grade III/IV 61,205 31.7 35,688 37.9 25,517 25.8
Unknown 7300 3.8 3428 3.6 3872 3.9
Histology
Ductal 151,631 78.6 76,477 81.3 75,154 76.0
Lobular 31,554 16.4 13,564 14.4 17,990 18.2
Other 9747 5.1 4035 4.3 5712 5.8
a Medicare-insured patients < 60 years of age were excluded
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non-Hispanic Black women had higher risk of dying re-
gardless of age group, although the HR was higher in
magnitude in younger than older patients. The opposite
pattern was observed for APIs who had lower risk of
dying compared to NHWs. These findings are consistent
with the well-established Non-Hispanic Black-White [1,
21] and API-White [1] mortality disparities previously
reported and confirms the consistency of these patterns
among older and younger women. The more pro-
nounced Black-White survival difference in younger
than older patients may reflect more aggressive disease
diagnosed among younger non-Hispanic Black women,
and warrants further study [1, 22]. No difference in
mortality was observed between Hispanics and NHWs
in either age group. Finally, results for nSES showed that
patients residing in lower socioeconomic neighborhoods
had higher breast cancer mortality compared to those in
higher socioeconomic neighborhoods, regardless of age.
Differences across insurance status in younger women
showed that compared to privately-insured women, those
in other insurance groups had a higher risk of dying, with
the highest risk shown in uninsured patients. Of note,
younger patients with Medicare insurance were excluded
since this group would likely include patients with worse
prognosis than those in the older group, complicating the
older vs. younger Medicare comparisons. Medicaid/pub-
licly insured patients and uninsured patients had higher
mortality compared to those with private insurance
regardless of age group although the HRs were higher for
younger women. These results suggest that health insur-
ance plays an important role in explaining disparities in
breast cancer mortality, as has been noted in the literature
[23, 24], and that these disparities are somewhat more
pronounced in younger women. Higher mortality in Me-
dicaid patients may be due to challenges with Medicaid
insurance processes, whereby patients do not get access to
Medicaid insurance until their diagnosis of breast cancer
is established. Results of some studies suggest differences
in treatment for Medicaid patients compared to privately
insured patients [25, 26], with Medicaid patients being less
likely to receive more aggressive treatment [26], lessening
with age [27], which could be due to older patients quali-
fying for Medicare. Our results draw similar conclusions
to these published reports. When compared to private
Table 2 Breast cancer specific hazard ratios comparing older to younger age at diagnosis, stratified by race/ethnicity, insurance
status, and neighborhood (block group) statewide SES quintile, California, 2005–2015
Younger (18–59)
No. deaths due to
breast cancer
Older (60+)
No. deaths due to
breast cancer
HR (95% CI)a
Older vs. Younger
(referent)
HR (95% CI)b
Older vs. Younger
(referent)
Overall 7058 7706 1.14 (1.10–1.18) 1.35 (1.29–1.40)
Race/ethnicity
Non-Hispanic White 3309 5199 1.29 (1.24–1.35) 1.43 (1.36–1.51)
Non-Hispanic Black 926 682 0.91 (0.83–1.01) 1.17 (1.04–1.31)
Hispanic 1892 1158 1.03 (0.96–1.11) 1.37 (1.26–1.50)
Asian/Pacific Islander 873 628 1.15 (1.04–1.27) 1.15 (1.02–1.31)
Other/unknown 58 39 0.75 (0.50–1.13) 0.56 (0.32–0.97)
Insurance statusc
Private only 4258 2606 1.18 (1.12–1.24) 1.51 (1.43–1.59)
Any Medicaid/Military/Other public 2360 1585 0.87 (0.82–0.93) 1.18 (1.10–1.26)
No insurance 169 76 0.96 (0.74–1.26) 1.05 (0.78–1.43)
Unknown 271 174 0.79 (0.65–0.95) 1.18 (0.96–1.45)
Neighborhood (block group)
statewide SES quintile
1st (lowest) 1375 1228 1.01 (0.93–1.09) 1.35 (1.23–1.48)
2nd 1482 1595 1.07 (0.99–1.15) 1.24 (1.14–1.36)
3rd 1509 1649 1.09 (1.02–1.17) 1.30 (1.19–1.41)
4th 1451 1670 1.19 (1.11–1.28) 1.43 (1.31–1.56)
5th (highest) 1241 1564 1.37 (1.27–1.48) 1.42 (1.29–1.56)
HR Hazard ratio, CI Confidence interval, No. Number
a Adjusted for year at diagnosis
b Stratified by AJCC stage and adjusted for year of diagnosis, marital status, race/ethnicity (in models not stratified by this), insurance status (in models not
stratified by this), nSES (in models not stratified by this), lymph node involvement, tumor subtype, tumor size, tumor grade, tumor histology, NCI-designated
cancer center and clustering by block group
c Medicare-insured patients < 60 years of age were excluded
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insurance, patients with Medicaid had higher mortality,
with higher risk in younger than older patients. Additional
research is needed to disentangle age differences in the
relationship of insurance status on breast cancer mortality.
Findings of our study need to be put into context of
limitations. Although results are based on population-
based data covering the entire state of California, given
the scarcity of published data on the age-related differ-
ences in mortality, these need further validation in other
population-based settings. Further, our survival analyses
were adjusted for important clinical characteristics.
Importantly, we are unable to account for comorbidities
because they are not collected as part of the cancer
registry. As such, our findings could be subject to re-
sidual confounding from incomplete treatment and co-
morbidity data in the cancer registry [28], which may be
especially relevant when comparing older and younger
patients. In addition, although it is likely that very young
women (< 40 years) have a higher risk of mortality than
older women [3], which could affect the results of our
study, excluding this younger group from the analysis
had no appreciable effect on the observed mortality
measures. We emphasize that due to limited data on this
topic, future population-based studies with more de-
tailed treatment, clinical comorbidity data than those
available in the registry are needed to validate our find-
ings and potentially explore mechanisms associated with
our observed age-related mortality differences.
Conclusions
Results from our population-based study show that older
breast cancer patients have higher risk of dying from
Table 3 Breast cancer specific hazard ratios stratified by age for race/ethnicity, health insurance, and neighborhood socioeconomic
status, California, 2005–2015
Younger (18–59) Older (60+)
No. deaths due to
breast cancer
HR (95%CI)a HR (95%CI)b No. deaths due to
breast cancer
HR (95%CI)a HR (95%CI)b
All 7058 7706
Race/ethnicity
Non-Hispanic White 3309 1.00 1.00 5199 1.00 1.00
Non-Hispanic Black 926 2.36 (2.20–2.54) 1.36 (1.25–1.48) 682 1.79 (1.66–1.94) 1.11 (1.01–1.22)
Hispanic 1892 1.42 (1.34–1.50) 0.95 (0.89–1.01) 1158 1.26 (1.18–1.34) 0.95 (0.88–1.02)
Asian/Pacific Islander 873 0.90 (0.84–0.97) 0.88 (0.82–0.95) 628 0.89 (0.81–0.96) 0.77 (0.70–0.84)
Other/unknown 58 0.91 (0.70–1.18) 0.83 (0.64–1.08) 39 0.58 (0.42–0.79) 0.50 (0.35–0.70)
P-interaction = < 0.0001c
Insurance status
Private only 4258 1.00 1.00 2606 1.00 1.00
Medicare only or Medicare+Private -d -d -d 3265 1.04 (0.98–1.10) 1.00 (0.94–1.05)
Any Medicaid/Military/Other public 2360 2.60 (2.47–2.74) 1.49 (1.41–1.58) 1585 1.73 (1.62–1.84) 1.13 (1.06–1.21)
No insurance 169 3.04 (2.61–3.54) 1.96 (1.65–2.32) 76 2.74 (2.18–3.44) 1.57 (1.22–2.03)
Unknown 271 1.47 (1.30–1.66) 1.11 (0.98–1.27) 174 0.92 (0.79–1.08) 0.86 (0.74–1.01)
P-interaction = < 0.0001c
Neighborhood (block group)
statewide SES quintile
1st (lowest) 1375 2.65 (2.45–2.86) 1.34 (1.22–1.46) 1228 1.93 (1.79–2.08) 1.38 (1.27–1.50)
2nd 1482 2.09 (1.93–2.25) 1.34 (1.24–1.45) 1595 1.60 (1.49–1.71) 1.28 (1.18–1.38)
3rd 1509 1.73 (1.61–1.87) 1.27 (1.17–1.37) 1649 1.36 (1.27–1.45) 1.19 (1.10–1.27)
4th 1451 1.38 (1.28–1.49) 1.13 (1.05–1.22) 1670 1.18 (1.10–1.26) 1.12 (1.04–1.20)
5th (highest) 1241 1.00 1.00 1564 1.00 1.00
P-interaction = 0.48c
HR Hazard ratio, CI Confidence interval, No. Number
a Adjusted for age at diagnosis and year at diagnosis
b Stratified by AJCC stage and adjusted for age of diagnosis, year of diagnosis, marital status, race/ethnicity, insurance status, nSES, lymph node involvement,
tumor subtype, tumor size, tumor grade, tumor histology, NCI-designated cancer center and clustering by block group
c P for interaction between age group (younger and older) and race/ethnicity, insurance status, or nSES from a model that included all significant interactions with
age group
d Medicare-insured patients < 60 years of age were excluded
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breast cancer compared with younger women, with dif-
ferences more pronounced for NHW, Hispanic, and
privately insured women. The prominent Black-White
mortality disparity among younger women warrants
further study of whether biology, access to treatment, or
other factors are driving the particularly poor survival
among young non-Hispanic Black women. Health insur-
ance plays an important role in in explaining age-related
differences in breast cancer mortality, with greater
disparities shown between privately- and non-privately-
insured patients in younger than older patients.
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